Lipohypertrophy: knowledge and education to treatment with insulin in diabetes mellitus

Lipohipertrofia: conocimiento y educación al tratamiento con insulina en la diabetes mellitus;
Lipohipertrofia: conhecimento e educação ao tratamento com insulina na diabete mellitus

dc.creatorCano Ibarra, Sandra Milena
dc.creatorLastre Amell, Gloria
dc.creatorOróstegui Santander, María Alejandra
dc.date2019-03-13
dc.date.accessioned2022-12-15T18:29:06Z
dc.date.available2022-12-15T18:29:06Z
dc.identifierhttps://revistas.unimilitar.edu.co/index.php/rmed/article/view/3984
dc.identifier10.18359/rmed.3984
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5357475
dc.descriptionIntroduction: Diabetes mellitus type 1 is a chronic disease that, once diagnosed, generates changes in the patient's lifestyle. In order to achieve optimal treatment and avoid subsequent complications, such as lipohypertrophy caused by the increase in the use of insulin, it is vital that patients and medical personnel receive adequate education, so that they acquire knowledge and skills related to the application of the insulin injection. Lipohypertrophy occurs due to the accumulation of subcutaneous fat at the site where insulin is repeatedly injected. Objective: To describe lipohy subject. Methodology: A review of the literature in the databases SciELO, Ovid, Medline, PubMed, ScienceDirect, and Elsevier was carried out, from which 71 articles we identified, and of which 50 met the criteria and were relevant to the search. Results: The most complete and pertinent information was selected from the databases regarding lipohypertrophy, knowledge, education, and insulin treatment in diabetes mellitus. Conclusion: This research allowed us to determine that lipohypertrophy, a secondary complication of insulin treatment in diabetes mellitus, is caused by factors such as an inadequate application technique and inadequate rotation of the injection sites, as well as the lack of knowledge that patients have regarding the treatment, and the lack of education of health personnel when it comes to the use of insulin application techniques.en-US
dc.descriptionIntroducción: la diabetes mellitus tipo 1 es una enfermedad crónica que, una vez diagnósticada, genera cambios en el estilo de vida del paciente. Para lograr un tratamiento óptimo y evitar complicaciones posteriores, como lipohipertrofia por el aumento en el uso de la insulina, es de vital importancia que se brinde a los pacientes y el personal médico una adecuada educación, para que adquieran conocimientos y habilidades en la aplicación de la inyección de insulina. La lipohipertrofia se presenta por acumulación de grasa subcutánea en el sitio donde se inyecta constantemente la insulina. Objetivo: describir la lipohipertrofia en pacientes con diabetes mellitus, los conocimientos y educación que debe adquirir con respecto al tema. Metodología: se realizó una revisión de literatura en las bases de datos SciELO, Ovid, Medline, PubMed, ScienceDirect y Elsevier, que permitió identificar 71 artículos, de los cuales 50 cumplían con los criterios y pertinencia de la búsqueda. Resultados: se seleccionó la información más completa y pertinente de las bases de datos, respecto a la lipohipertrofia, conocimiento, educación y tratamiento con insulina en la diabetes Mellitus. Conclusión: esta revisión permitió determinar que la lipohipertrofia, una complicación secundaria del tratamiento con insulina en la diabetes Mellitus; se origina en factores tales como la técnica de aplicación y rotación inadecuadas de los puntos de inyección, el escaso conocimiento de los pacientes acerca del tratamiento y la falta de educación del personal sanitario con respecto al uso de las técnicas de aplicación de la insulina.es-ES
dc.descriptionIntrodução. A diabetes mellitus tipo 1 é uma doença crônica que, uma vez diagnosticada, gera mudanças no estilo de vida do paciente. Para obter um tratamento ótimo e evitar complicações posteriores, como lipohipertrofia pelo aumento no uso da insulina, é de vital importância proporcionar aos pacientes e o pessoal médico uma adequada educação, para que adquiram conhecimentos e habilidades na aplicação da injeção de insulina. A lipohipertrofia se apresenta por acumulação de gordura subcutânea no lugar onde se injeta constantemente a insulina. Objetivo: descrever a lipohipertrofia em pacientes com diabetes mellitus, os conhecimentos e educação que deve adquirir com respeito ao tema. Metodologia: se realizou una revisão de literatura nas bases de dados SciELO, Ovid, Medline, PubMed, ScienceDirect, Elsevier, que permitiu identificar 71 artigos, dos quais 50 cumpriam com os critérios e pertinência da busca. Resultados: selecionou-se a informação mais completa e pertinente das bases de dados, com relação à lipohipertrofia, conhecimento, educação e tratamento com insulina na diabetes Mellitus. Conclusão: esta revisão permitiu determinar que a lipohipertrofia, uma complicação secundária do tratamento com insulina na diabetes Mellitus, origina-se em fatores tais como a técnica de aplicação e rotação inadequadas dos pontos de injeção, o escasso conhecimento dos pacientes sobre o tratamento e a falta de educação do pessoal sanitário com relação ao uso das técnicas de aplicação da insulina.pt-BR
dc.formatapplication/pdf
dc.formatapplication/xml
dc.languagespa
dc.publisherUniversidad Militar Nueva Granadaes-ES
dc.relationhttps://revistas.unimilitar.edu.co/index.php/rmed/article/view/3984/3074
dc.relationhttps://revistas.unimilitar.edu.co/index.php/rmed/article/view/3984/3301
dc.relation/*ref*/UK Prospective Diabetes Study Group. Intensive bloodglucose control with sulphonylureas or insulin compared to conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
dc.relation/*ref*/Strauss K, De Gols H, Hannet I, Partanen TM, Frid A. A pan-European epidemiologic study of insulin injection technique in patients with diabetes. Pract Diab Int. 2002; 19(3): 71–6.
dc.relation/*ref*/Volkova N, Davidenko I. Lypohypertrophy in patients receiving insulin therapy: state of the art. Diabetes Mellitus. Diagn Manag Treat. 2011; 2: 80–3.
dc.relation/*ref*/Wallymahmed M, Littler P, Clegg C., Haqqani M. & Mac-Farlane, I. A. “Nodules of Fibrocollagenous Scar Tissue Induced by Subcutaneous Insulin Injections: A Cause of Poor Diabetic Control,” Postgraduate Medicine Journal, 2004; 80 (950): 732-3.
dc.relation/*ref*/Hofman P, et al. “Defining the Ideal Injection Techniques when Using 5-mm Needles in Children and Adults,” Diabetes Care, 2010; 33 (9): 1940-4.
dc.relation/*ref*/Dar I, Dar S, Wani S. Insulin lipohypertrophy: A non-fatal dermatological complication of diabetes mellitus reflecting poor glycemic control. Saudi Journal of Medicine and Medical Sciences, 2013. 1(2): 106–8.
dc.relation/*ref*/Röcken M, Strölin A. Hautkrankenheiten und Diabetes Mellitus. In: Häring HU, Gallwitz B, Müller-Wieland D, Klaus-Henning V, Mehnert H. Diabetologie in Klinik und Praxis. Deutchsland: 6 Auflage; 2011. p. 524-9.
dc.relation/*ref*/Heinemann L. Insulin absorption from lipodystrophic areas: a (neglected) source of trouble for insulin therapy? J Diabetes Sci Technol. 2010; 4(3): 750-3.
dc.relation/*ref*/Behm B, et al. Skin signs in diabetes mellitus. J Eur Acad Dermatol Venereol. 2012; 26(10): 1203-11.
dc.relation/*ref*/Murphy-Chutorian B, Han G, Cohen SR. Dermatologic manifestations of diabetes mellitus: a review. Endocrinol Metab Clin North Am. 2013; 42(4): 869-98.
dc.relation/*ref*/Van Hattem S, Bootsma A, Thio H. Skin manifestations of diabetes. Cleve Clin J Med. 2008; 75(11): 772, 774, 776-7 passim.
dc.relation/*ref*/Alemzadeh R, Loppnow C, Parton E, Kirby M. Glucose sensor evaluation of glycemic instability in pediatric type 1 diabetes mellitus. Diabetes Technol Ther 2003; 5: 167–73.
dc.relation/*ref*/Thow J, Johnson A, Marsden S, Taylor R, Home PD. Morphology of palpably abnormal injection sites and effects on absorption of isophane (NPH) insulin. Diabet Med. 1990; 7: 795–9.
dc.relation/*ref*/Young R, Hannan W, Frier B, Steel J, Duncan L. Diabetic lipohypertrophy delays insulin absorption. Diabetes Care. 1984; 7: 479–80.
dc.relation/*ref*/Griffin M, Feder A, Tamborlane W. Lipoatrophy associated with lispro insulin in insulin pump therapy: an old complication, a new cause? Diabetes Care. 2001; 24(1): 174.
dc.relation/*ref*/Del Olmo M, Campos V, Abellán P, Merino-Torres J, Piñón F. A case of lipoatrophy with insulin detemir. Diabetes Res Clin Pract. 2008; 80(1): e20–1.
dc.relation/*ref*/Ampudia J, Hasbum B, Carmena R. A new case of lipoathrophy with lispro insulin in insulin pump therapy: is there any insulin preparation free of complications? Diabetes Care. 2003; 26(3): 953–4.
dc.relation/*ref*/Radermecker R, Piérard G, Scheen A. Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs. Am J Clin Dermatol. 2007; 8(1): 21–8.
dc.relation/*ref*/Perciun R, Mihu M. The Subcutis Ultrasound Map of Type 1 Diabetic Children Improves the Diagnosis of Local Dystrophies and Insulin Injection Technique, Pediatrics Research International Journal, Vol. 2014 (2014). DOI: 10.5171/2014.402780
dc.relation/*ref*/Perciun, R. “Aspecto ecográfico del tejido subcutáneo Distrofias como resultado de inyecciones de insulina,” Médico ecografía, 2010; 12 (2): 104-9.
dc.relation/*ref*/Manjula G, Saravana A. Problems Associated with insulin administration among patients with type 2 Diabetes Mellitus. Impact Factor (2013): 4.438.
dc.relation/*ref*/Van Munster, H, et al. Dermatological complications of insulin therapy in children with type 1 diabetes. European Diabetes Nursing. 2014; 11(3): 79-84.
dc.relation/*ref*/Omar M, El-Kafoury A, El-Araby R. Lipohypertrophy in children and adolescents with type 1 diabetes and the associated factors. BMC Research Notes 2011, 4: 290.
dc.relation/*ref*/Annersten M, Wilman A. Performing subcutaneous injections: A literature review. Wordviews on Evid Based Nurs. 2005 [citado 22 MAY 2016]; 2(3): 122-30.
dc.relation/*ref*/Al Ajlouni M, Abujbara M, Batieha A, Ajlouni K. Prevalence of Lipohypertrophy and associated risk factors in insulin-treated patients with type 2 diabetes mellitus. nt J Endocrinol Metab. 2015 Apr; 13(2): e20776.
dc.relation/*ref*/Malwa G, Balami D, Deshmukh S, Groft M, Bodmer C, Patel M. Insulin-induced Lipohypertrophy, past present and future: are we lose the bottle. Endocrine. 2010; 22: 268.
dc.relation/*ref*/Hajheydari Z, Kashi Z, Akha O, Akbarzadeh S. Frequency of lipodystrophy induced by recombinant human insulin. Eur Rev Med Pharmacol Sci. 2011 Oct; 15(10): 1196-201.
dc.relation/*ref*/Ji J, Lou Q. Insulin pen injection technique survey in patients with type 2 diabetes in mainland China in 2010. 2014 Jun; 30(6): 1087-93.
dc.relation/*ref*/Babiker A, Datta V. Lipoatrophy with insulin analogues in type I diabetes. Arch Dis Child published online June 22, 2010. Doi: 10.1136/adc.2010.183731
dc.relation/*ref*/DeSalvo DJ, Shanmugham S, Ly TT, Wilson DM, Buckingham BA. Accuracy evaluation of blood glucose monitoring systems in childrenon overnight closed-loop control. J Diabetes Sci Technol 2014; 8: 969–73.
dc.relation/*ref*/Heinemann L, Hirsch L, Hovorka R. Lipohy pertrophy and the artificial pancreas: is this an issue? J Diabetes Sci Technol 2014; 8: 915–7.
dc.relation/*ref*/DeSalvo DJ, et al. Effect of Lipohypertrophy on accuracy of continuous glucose monitoring in patients with type 1 diabetes. Diabetes Care. August 25, 2015. pii: dc151267
dc.relation/*ref*/Cunningham MT, McKenna MJ. Lipohypertrophy in insulin-treated diabetes: Prevalence and associated risk factors. Journal of Diabetes Nursing. 2013 17: 340–3.
dc.relation/*ref*/Pettis R, et al. “Intradermal Microneedle Delivery of Insulin Lispro Achieves Faster Insulin Absorption and Insulin Action than Subcutaneous Injection,” Diabetes Technology & Therapeutics, 2011; 13(4): 435-42.
dc.relation/*ref*/Goupta J, Felner E. & Prausnitz R. “Rapid Pharmacokinetics of Intradermal Insulin Administered Using Microneedles in Type 1 Diabetes Subjects,” Diabetes Technology & Therapeutics, 2011; 13(4): 451-6.
dc.relation/*ref*/Merino J. Nuevas tecnologías en el seguimiento y control del paciente diabético Editorial De La Sociedad Española De Diabetes. 2007.
dc.relation/*ref*/Saltiel-Berzin R, Cypress M, Gibney M. Translating the research in insulin injection technique: implications for practice. Diabetes Educ. 2012 Sep-Oct; 38(5): 635-43.
dc.relation/*ref*/Lo Presti D, Ingegnosi C, Strauss K. Skin and subcutaneous thickness at injecting sites in children with diabetes: ultrasound findings and recommendations for giving injection. 2012 Nov; 13(7): 525-33.
dc.relation/*ref*/Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. 2013; 39(5): 445–53.
dc.relation/*ref*/Grassi G, Scuntero P, Trepiccioni R, Marubbi F, Strauss K. Optimizing insulin injection technique and its effect on blood glucose control. Journal of Clinical & Translational Endocrinology. 2014; 1(4): 145–50.
dc.relation/*ref*/Bergenstal RM, et al. Safety and efficacy of insulin therapy delivered via a 4mm pen needle in obese patients with diabetes. 2015; 90(3): 329-38.
dc.relation/*ref*/Saltiel-Berzin R, Cypress M, Gibney M. Translating the research in insulin injection technique: implications for practice. Diabetes Educ. 2012; 38(5): 635-43.
dc.relation/*ref*/Al Ajlouni M, Abujbara M, Batieha A, Ajlouni K. prevalence of lipohypertrophy and associated risk factors in insulin-treated patients with type 2 diabetes mellitus. J Endocrinol Metab. 2015; 13(2): e20776.
dc.relation/*ref*/Stanley Landau, F.C.P.(S.A.). Insulin-Induced Lipohypertrophy. N Engl J Med 2012; 366: e9.
dc.relation/*ref*/Frid A, et al. New injection recommendations for patients with diabetes. September 2010. 36(s2): s3–s18.
dc.relation/*ref*/Gibney M, Arce, C, Byron K. & Hirsch L. Skin and Subcutaneous Adipose Layer Thickness in Adults with Diabetes at Sites Used for Insulin Injections: Implications for Needle Length Recommendations. Current Medical Research & Opinion, 2010; 26(6): 1519-30.
dc.relation/*ref*/Selkow N, Pietrosimone B& Saliba S. A. Subcutaneous Thigh Fat Assessment: A Comparison of Skinfold Calipers and Ultrasound Imaging. Journal of Athletic Training, 2011; 46 (1): 50-4.
dc.relation/*ref*/Mokta J, Mokta K, Panda P. Insulin lipodystrophy and lipohypertrophy. Indian J Endocrinol Metab. 2013; 17: 773-4.
dc.relation/*ref*/Pledger J, Hicks D, Kirkland F, Down S. Importance of injection technique in diabetes. Journal of Diabetes Nursing; 2012, 16(4): 160.
dc.relation/*ref*/Nagesh V, Kalra S. Type 1 diabetes: Syndromes in resource- challenged settings. J Pak Med Assoc. 2015 Jun; 65(6): 681-5.
dc.rightsDerechos de autor 2019 Revista Medes-ES
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0es-ES
dc.sourceRevista Med; Vol. 26 No. 1 (2018): january - june; 64-71en-US
dc.sourceRevista Med; Vol. 26 Núm. 1 (2018): enero - junio; 64-71es-ES
dc.source1909-7700
dc.source0121-5256
dc.subjectHypertrophyen-US
dc.subjectknowledgeen-US
dc.subjecteducationen-US
dc.subjectMellitus diabetesen-US
dc.subjectinsulin.en-US
dc.subjectHipertrofiaes-ES
dc.subjectconocimientoes-ES
dc.subjecteducaciónes-ES
dc.subjectdiabetes mellituses-ES
dc.subjectinsulina.es-ES
dc.subjectHipertrofiapt-BR
dc.subjectconhecimentopt-BR
dc.subjecteducaçãopt-BR
dc.subjectdiabetes mellituspt-BR
dc.subjectinsulina.pt-BR
dc.titleLipohypertrophy: knowledge and education to treatment with insulin in diabetes mellitusen-US
dc.titleLipohipertrofia: conocimiento y educación al tratamiento con insulina en la diabetes mellituses-ES
dc.titleLipohipertrofia: conhecimento e educação ao tratamento com insulina na diabete mellituspt-BR
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución